



LEGISLATURE OF THE STATE OF IDAHO



Sixty-sixth Legislature

Second Regular Session - 2022

IN THE _____

BILL NO. _____

BY _____

AN ACT

RELATING TO UNIFORM CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO REVISE PROVISIONS REGARDING SCHEDULE I CONTROLLED SUBSTANCES; AMENDING SECTION 37-2707, IDAHO CODE, TO REVISE PROVISIONS REGARDING SCHEDULE II CONTROLLED SUBSTANCES; AMENDING SECTION 37-2711, IDAHO CODE, TO REVISE PROVISIONS REGARDING SCHEDULE IV CONTROLLED SUBSTANCES; AND AMENDING SECTION 37-2713, IDAHO CODE, TO REVISE PROVISIONS REGARDING SCHEDULE V CONTROLLED SUBSTANCES.

Be It Enacted by the Legislature of the State of Idaho:

SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby amended to read as follows:

37-2705. SCHEDULE I. (a) The controlled substances listed in this section are included in schedule I.

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:

- (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
- (2) Acetylmethadol;
- (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
- (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide);
- (5) Allylprodine;
- (6) Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);
- (7) Alphameprodine;
- (8) Alphamethadol;
- (9) Alpha-methylfentanyl;
- (10) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
- (11) Benzethidine;
- (12) Betacetylmethadol;
- (13) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);
- (14) Beta-hydroxythiofentanyl;
- (15) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide);
- (15~~6~~) Betameprodine;
- (16~~7~~) Betamethadol;
- (18) Beta-methyl fentanyl;



1 (19) Beta'-phenyl fentanyl;
2 ~~(1720) Betaprodine;~~
3 (21) Brorphine (1-(1-(1-(4-Bromophenyl)ethyl)piperidin-4-yl)-1,3-
4 dihydro-2H-benzo[D]imidazol-2-one);
5 ~~(1822) Clonitazene;~~
6 (23) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenyl-
7 but-2-enamide);
8 ~~(1924) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyl-~~
9 ~~cyclopentanecarboxamide);~~
10 (205) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyl-
11 cyclopropanecarboxamide);
12 (216) Dextromoramide;
13 (227) Diampromide;
14 (238) Diethylthiambutene;
15 (249) Difenoxin;
16 (2530) Dimenoxadol;
17 (2631) Dimepheptanol;
18 (2732) Dimethylthiambutene;
19 (2833) Dioxaphetyl butyrate;
20 (2934) Dipipanone;
21 (305) Ethylmethylthiambutene;
22 (316) Etonitazene;
23 (327) Etoxeridine;
24 (338) Fentanyl-related substances. "Fentanyl-related substances"
25 means any substance not otherwise listed and for which no exemption or
26 approval is in effect under section 505 of the federal food, drug, and
27 cosmetic act, 21 U.S.C. 355, and that is structurally related to fen-
28 tanyl by one (1) or more of the following modifications:
29 i. Replacement of the phenyl portion of the phenethyl group by any
30 monocycle, whether or not further substituted in or on the monocy-
31 cle;
32 ii. Substitution in or on the phenethyl group with alkyl, alkenyl,
33 alkoxy, hydroxyl, halo, haloalkyl, amino, or nitro groups;
34 iii. Substitution in or on the piperidine ring with alkyl,
35 alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl, amino,
36 or nitro groups;
37 iv. Replacement of the aniline ring with any aromatic monocycle,
38 whether or not further substituted in or on the aromatic monocy-
39 cle; and/or
40 v. Replacement of the N-propionyl group by another acyl group;
41 (39) Fentanyl carabamate;
42 (340) 4-Fluoroisobutyl fentanyl (N-(4-fluorophenyl)-N-(1-
43 phenethylpiperidin-4-yl)isobutyramide);
44 (41) 2'-fluoro ortho-fluorofentanyl;
45 (3542) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfu-
46 ran-2-carboxamide);
47 (436) Furethidine;
48 (3744) Hydroxypethidine;
49 (3845) Isobutyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
50 phenylisobutyramide);

1 (46) Isotonitazene (N,N-diethyl-2-(2-(4isopropoxybenzyl)-5-ni-
2 tro-1h-benzimidazol-1-yl)ethan-1-amine);
3 (3947) Ketobemidone;
4 (408) Levomoramide;
5 (419) Levophenacylmorphane;
6 (50) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-
7 yl)-N-phenylacetamide;
8 (51) 4'-methyl acetyl fentanyl;
9 (452) 3-Methylfentanyl;
10 (453) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-
11 eridinyl]-N-phenylpropanamide);
12 (454) Morpheridine;
13 (455) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
14 (456) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
15 (57) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl) Isobutyramide
16 (para-chloroisobutyryl fentanyl);
17 (4758) Noracymethadol;
18 (4859) Norlevorphanol;
19 (4960) Normethadone;
20 (5061) Norpipanone;
21 (5162) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-
22 phenethylpiperidin-4-yl) acetamide);
23 (63) Ortho-fluoroacetyl fentanyl;
24 (64) Ortho-fluorobutyryl fentanyl;
25 (65) Ortho-fluorofentanyl;
26 (66) Ortho-fluoroisobutyryl fentanyl;
27 (67) Ortho-methyl acetylfentanyl;
28 (68) Ortho-methyl methoxyacetyl fentanyl;
29 (5269) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-
30 phenethylpiperidin-4-yl) isobutyramide);
31 (5370) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
32 phenethylpiperidin-4-yl) butyramide);
33 (5471) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phen-
34 ethyl)-4-piperidinyl] propanamide);
35 (72) Para-fluoro furanyl fentanyl;
36 (5573) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-
37 phenethylpiperidin-4-yl) butyramide);
38 (74) Para-methylfentanyl;
39 (756) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
40 (576) Phenadoxone;
41 (5877) Phenampromide;
42 (5978) Phenomorphan;
43 (6079) Phenoperidine;
44 (80) Phenyl fentanyl;
45 (681) Piritramide;
46 (682) Proheptazine;
47 (683) Properidine;
48 (684) Propiram;
49 (685) Racemoramide;



- 1 (~~686~~) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidine-4-yl)-N-
2 phenyltetrahydrofuran-2-carboxamide);
3 (~~687~~) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
4 propanamide);
5 (~~688~~) Tilidine;
6 (~~689~~) Trimeperidine;
7 (~~790~~) u-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
8 methylbenzamide);
9 (~~791~~) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpen-
10 tanamide).

11 (c) Any of the following opium derivatives, their salts, isomers and
12 salts of isomers, unless specifically excepted, whenever the existence of
13 these salts, isomers and salts of isomers is possible within the specific
14 chemical designation:

- 15 (1) Acetorphine;
16 (2) Acetyldihydrocodeine;
17 (3) Benzylmorphine;
18 (4) Codeine methylbromide;
19 (5) Codeine-N-Oxide;
20 (6) Cyprenorphine;
21 (7) Desomorphine;
22 (8) Dihydromorphine;
23 (9) Drotebanol;
24 (10) Etorphine (except hydrochloride salt);
25 (11) Heroin;
26 (12) Hydromorphenol;
27 (13) Methyldesorphine;
28 (14) Methyldihydromorphine;
29 (15) Morphine methylbromide;
30 (16) Morphine methylsulfonate;
31 (17) Morphine-N-Oxide;
32 (18) Myrophine;
33 (19) Nicocodeine;
34 (20) Nicomorphine;
35 (21) Normorphine;
36 (22) Pholcodine;
37 (23) Thebacon.

38 (d) Hallucinogenic substances. Any material, compound, mixture or
39 preparation ~~which~~ that contains any quantity of the following hallucino-
40 genic substances, their salts, isomers and salts of isomers, unless specifi-
41 cally excepted, whenever the existence of these salts, isomers, and salts of
42 isomers is possible within the specific chemical designation (for purposes
43 of this paragraph only, the term "isomer" includes the optical, position and
44 geometric isomers):

- 45 (1) Dimethoxyphenethylamine, or any compound not specifically
46 excepted or listed in another schedule that can be formed from
47 dimethoxyphenethylamine by replacement of one (1) or more hydrogen
48 atoms with another atom(s), functional group(s) or substructure(s)
49 including, but not limited to, compounds such as DOB, DOC, 2C-B,
50 25B-NBOMe;



- 1 (2) Methoxyamphetamine or any compound not specifically excepted or
- 2 listed in another schedule that can be formed from methoxyamphetamine
- 3 by replacement of one (1) or more hydrogen atoms with another atom(s),
- 4 functional group(s) or substructure(s) including, but not limited to,
- 5 compounds such as PMA and DOM;
- 6 (3) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 7 (4) 5-methoxy-N,N-diisopropyltryptamine;
- 8 (5) Amphetamine or methamphetamine with a halogen substitution on the
- 9 benzyl ring, including compounds such as fluorinated amphetamine and
- 10 fluorinated methamphetamine;
- 11 (6) 3,4-methylenedioxy amphetamine;
- 12 (7) 3,4-methylenedioxymethamphetamine (MDMA);
- 13 (8) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-
- 14 hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-
- 15 hyl MDA, MDE, MDEA);
- 16 (9) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-
- 17 roxy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-hyd-
- 18 roxy MDA);
- 19 (10) 3,4,5-trimethoxy amphetamine;
- 20 (11) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-2[2-
- 21 (dimethylamino)ethyl]indole and 5-MeO-DMT);
- 22 (12) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-
- 23 inobutyl) indole);
- 24 (13) Alpha-methyltryptamine;
- 25 (14) Bufotenine;
- 26 (15) Diethyltryptamine (DET);
- 27 (16) Dimethyltryptamine (DMT);
- 28 (17) Ibogaine;
- 29 (18) Lysergic acid diethylamide;
- 30 (19) Marihuana;
- 31 (20) Mescaline;
- 32 (21) Parahexyl;
- 33 (22) Peyote;
- 34 (23) N-ethyl-3-piperidyl benzilate;
- 35 (24) N-methyl-3-piperidyl benzilate;
- 36 (25) Psilocybin;
- 37 (26) Psilocyn;
- 38 (27) Tetrahydrocannabinols or synthetic equivalents of the substances
- 39 contained in the plant, or in the resinous extractives of Cannabis, sp.
- 40 and/or synthetic substances, derivatives, and their isomers with simi-
- 41 lar chemical structure such as the following:
- 42 i. Tetrahydrocannabinols, except for the permitted amount of
- 43 tetrahydrocannabinol found in industrial hemp:
- 44 a. Δ^1 cis or trans tetrahydrocannabinol, and their opti-
- 45 cal isomers, excluding dronabinol in sesame oil and encapsu-
- 46 lated in either a soft gelatin capsule or in an oral solution
- 47 in a drug product approved by the U.S. Food and Drug Adminis-
- 48 tration.
- 49 b. Δ^6 cis or trans tetrahydrocannabinol, and their optical
- 50 isomers.

- 1 c. $\Delta^{3,4}$ cis or trans tetrahydrocannabinol, and its optical
2 isomers. (Since nomenclature of these substances is not in-
3 ternationally standardized, compounds of these structures,
4 regardless of numerical designation of atomic positions are
5 covered.)
- 6 d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methyl-
7 octan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-
8 1-ol)], also known as 6aR-trans-3-(1,1-dimethylhept-
9 tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
10 dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric
11 isomers (HU211 or dexanabinol).
- 12 ii. The following synthetic drugs:
- 13 a. Any compound structurally derived from (1H-indole-3-
14 yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-
15 dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or
16 (1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl), methyl
17 or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-
18 tan-2-yl) carboxamide by substitution at the nitrogen atoms
19 of the indole ring or carboxamide to any extent, whether or
20 not further substituted in or on the indole ring to any ex-
21 tent, whether or not substituted to any extent in or on the
22 cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the
23 ring may include, but is not limited to, heteroatoms such as
24 nitrogen, sulfur and oxygen).
- 25 b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoro-
26 ropentyl)-1H-indazole-3-carboxamide (5F-AB-PINACA).
- 27 c. 1-(1.3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
28 (N-ethylpentylone, ephylone).
- 29 d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-inda-
30 zole-3-carboxamide (4-cn-cumyl-BUTINACA).
- 31 e. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carbox-
32 amido)-3,3-dimethylbutanoate * (~~5f-cumyl-pinaca~~ 5F-EDMB-
33 PINACA).
- 34 f. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetram-
35 ethylcyclopropyl)methanone (fub-144).
- 36 g. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-
37 zole-3-carboxamide (5f-cumyl-pinaca; sgt25).
- 38 h. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
39 H-pyrrolo[2.3-B]pyridine-3-carboxamide (5fcumyl-P7AICA).
- 40 i. FUB-AMB, MMB- FUBINACA (Methyl 2-(1-(4-fluoroben-
41 zyl)-1H-indazole-3-carboxamido)-3-methylbutanoate.
- 42 j. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
43 ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).
- 44 jk. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
45 ido)-3,3-dimethylbutanoate (MDMB-CHMICA).
- 46 kl. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-
47 ido)-3,3-dimethylbutanoate (MDMB-FUBINACA).
- 48 lm. Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxam-
49 ido)-3,3-dimethylbutanoate (5F-MDMBPICA).

- 1 nn. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
2 ido)-3,3-dimethylbutanoate (5F-ADB, 5FMDMB-PINACA).
3 no. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
4 ido)-3-methylbutanoate (5FAMB).
5 op. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluo-
6 robenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).
7 og. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-inda-
8 zole-3-carboxamide (FUB-AKB48; FUB-APINACA).
9 or. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-inda-
10 zole-3-carboxamide (5F-APINACA, 5F-AKB48).
11 s. N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(Cyclohexyl-
12 methyl)-1H-indazole-3-carboxamide (AB-CHMINACA).
13 tt. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-car-
14 boxylate (NM2201; CBL2201).
15 su. Any compound structurally derived from 3-(1-naph-
16 thoyl)pyrrole by substitution at the nitrogen atom of the
17 pyrrole ring to any extent, whether or not further sub-
18 stituted in the pyrrole ring to any extent, whether or not
19 substituted in the naphthyl ring to any extent.
20 tv. Any compound structurally derived from 1-(1-naphthyl-
21 methyl)indene by substitution at the 3-position of the in-
22 dene ring to any extent, whether or not further substituted
23 in the indene ring to any extent, whether or not substituted
24 in the naphthyl ring to any extent.
25 uw. Any compound structurally derived from 3-phenyl-
26 lacetylindole by substitution at the nitrogen atom of the
27 indole ring to any extent, whether or not further substi-
28 tuted in the indole ring to any extent, whether or not sub-
29 stituted in the phenyl ring to any extent.
30 vx. Any compound structurally derived from 2-(3-hydroxy-
31 cyclohexyl)phenol by substitution at the 5-position of the
32 phenolic ring to any extent, whether or not substituted in
33 the cyclohexyl ring to any extent.
34 wy. Any compound structurally derived from 3-(benzoyl)in-
35 dole structure with substitution at the nitrogen atom of
36 the indole ring to any extent, whether or not further sub-
37 stituted in the indole ring to any extent and whether or not
38 substituted in the phenyl ring to any extent.
39 xz. [2,3-dihydro-5-methyl-3-(4-morpholinyl-
40 methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
41 naphthalenylmethanone (WIN-55,212-2).
42 yaa. 3-dimethylheptyl-11-hydroxyhexahydrocannabi-
43 nol (HU-243).
44 zbb. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-
45 5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-
46 drophenanthridin-1-yl]acetate (CP 50,5561).
47 (28) Ethylamine analog of phencyclidine:N-ethyl-1-phenylcy-
48 clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-
49 clohexyl) ethylamine, cyclohexamine, PCE;

- 1 (29) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -
2 pyrrolidine, PCPy, PHP;
- 3 (30) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-
4 piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;
- 5 (31) Thiofuranyl fentanyl;
- 6 (32) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;
- 7 (323) Spores or mycelium capable of producing mushrooms that contain
8 psilocybin or psilocin.
- 9 (e) Unless specifically excepted or unless listed in another schedule,
10 any material, compound, mixture or preparation which contains any quantity
11 of the following substances having a depressant effect on the central ner-
12 vous system, including its salts, isomers, and salts of isomers whenever the
13 existence of such salts, isomers, and salts of isomers is possible within the
14 specific chemical designation:
- 15 (1) Gamma hydroxybutyric acid (some other names include GHB; gam-
16 ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hydroxybutanoic acid; sod-
17 ium oxybate; sodium oxybutyrate);
- 18 (2) Flunitrazepam (also known as "R2," "Rohypnol");
- 19 (3) Mecloqualone;
- 20 (4) Methaqualone.
- 21 (f) Stimulants. Unless specifically excepted or unless listed in an-
22 other schedule, any material, compound, mixture, or preparation which con-
23 tains any quantity of the following substances having a stimulant effect on
24 the central nervous system, including its salts, isomers, and salts of iso-
25 mers:
- 26 (1) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-ox-
27 azoline, or 4,5-dihydro-5-phenyl-2-oxazolamine);
- 28 (2) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-
29 ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);
- 30 (3) Substituted cathinones. Any compound, except bupropion or com-
31 pounds listed under a different schedule, structurally derived from
32 2-aminopropan-1-one by substitution at the 1-position with either
33 phenyl, naphthyl or thiophene ring systems, whether or not the compound
34 is further modified in any of the following ways:
- 35 i. By substitution in the ring system to any extent with alkyl,
36 alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide sub-
37 stituents, whether or not further substituted in the ring system
38 by one (1) or more other univalent substituents;
- 39 ii. By substitution at the 3-position with an acyclic alkyl sub-
40 stituent;
- 41 iii. By substitution at the 2-amino nitrogen atom with alkyl,
42 dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the
43 2-amino nitrogen atom in a cyclic structure.
- 44 (4) Alpha-pyrrolidinoheptaphenone* (PV8);
- 45 (5) Alpha-pyrrolidinohexanophenone* (a-php);
- 46 (6) 4-chloro-alpha-pyrrolidinovalerophenone* (4chloro-a-pvp);
- 47 (7) Fenethylamine;
- 48 (8) Methcathinone (some other names: 2-(methyl-amino)-propioph-
49 enone, alpha-(methylamino)-propiophenone, N-methylcathinone, AL-
50 464, AL-422, AL-463 and UR1423);

- 1 (9) (+/-) cis-4-methylaminorex [(+/-) cis-4,5-dihydro-4-methyl-5-
2 phenyl-2-oxazolamine];
3 (10) 4-methyl-alpha-ethylaminopentiophenone* (~~4meap~~-MEAP);
4 (11) 4'-methyl-alpha-pyrrolidinohexiophenone* (mphp);
5 (12) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);
6 (13) N-ethylamphetamine;
7 (14) N-ethylhexedrone*;
8 (15) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-
9 benzeneethanamine).

10 SECTION 2. That Section 37-2707, Idaho Code, be, and the same is hereby
11 amended to read as follows:

12 37-2707. SCHEDULE II. (a) Schedule II shall consist of the drugs and
13 other substances, by whatever official name, common or usual name, chemical
14 name, or brand name designated, listed in this section.

15 (b) Substances, vegetable origin or chemical synthesis. Unless
16 specifically excepted or unless listed in another schedule, any of the fol-
17 lowing substances whether produced directly or indirectly by extraction
18 from substances of vegetable origin, or independently by means of chemical
19 synthesis, or by a combination of extraction and chemical synthesis:

20 (1) Opium and opiate, and any salt, compound, derivative, or prepa-
21 ration of opium or opiate, excluding apomorphine, dextrorphan, nal-
22 buphine, nalmeffene, naloxone, naltrexone and their respective salts,
23 but including the following:

- 24 1. Raw opium;
25 2. Opium extracts;
26 3. Opium fluid extracts;
27 4. Powdered opium;
28 5. Granulated opium;
29 6. Tincture of opium;
30 7. Codeine;
31 8. Dihydroetorphine;
32 9. Diprenorphine;
33 10. Ethylmorphine;
34 11. Etorphine hydrochloride;
35 12. Hydrocodone;
36 13. Hydromorphone;
37 14. Metopon;
38 15. Morphine;
39 16. Oripavine;
40 17. Oxycodone;
41 18. Oxymorphone;
42 19. Tapentadol;
43 20. Thebaine.

44 (2) Any salt, compound, derivative, or preparation thereof which is
45 chemically equivalent or identical with any of the substances referred
46 to in paragraph (1) of this subsection, except that these substances
47 shall not include the isoquinoline alkaloids of opium.

48 (3) Opium poppy and poppy straw.

- 1 (4) Coca leaves and any salt, compound, derivative, or preparation
2 of coca leaves, and any salt, compound, derivative, or preparation
3 thereof which is chemically equivalent or identical with any of these
4 substances, but shall not include the following:
5 1. Decocainized coca leaves or extractions of coca leaves, which
6 extractions do not contain cocaine; or ecgonine; or
7 2. [¹²³I]ioflupane.
8 (5) Benzoylecgonine.
9 (6) Methylbenzoylecgonine (Cocaine - its salts, optical isomers, and
10 salts of optical isomers).
11 (7) Concentrate of poppy straw (the crude extract of poppy straw in liq-
12 uid, solid or powder form that contains the phenanthrine alkaloids of
13 the opium poppy).
14 (c) Any of the following opiates, including their isomers, esters,
15 ethers, salts, and salts of isomers, whenever the existence of these iso-
16 mers, esters, ethers and salts is possible within the specific chemical
17 designation, unless specifically excepted or unless listed in another
18 schedule:
19 (1) Alfentanil;
20 (2) Alphaprodine;
21 (3) Anileridine;
22 (4) Bezitramide;
23 (5) Bulk Dextropropoxyphene (nondosage forms);
24 (6) Carfentanil;
25 (7) Dihydrocodeine;
26 (8) Diphenoxylate;
27 (9) Fentanyl;
28 (10) Isomethadone;
29 (11) Levo-alphaacetylmethadol (also known as levo-alpha-acetylmet-
30 hadol, levomethadyl acetate, LAAM);
31 (12) Levomethorphan;
32 (13) Levorphanol;
33 (14) Metazocine;
34 (15) Methadone;
35 (16) Methadone -- Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl
36 butane;
37 (17) Moramide -- Intermediate, 2-methyl-3-morpholino-1, 1-diphenyl
38 propane-carboxylic acid;
39 (18) Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide);
40 (19) Oliceridine;
41 (20) Pethidine (meperidine);
42 (201) Pethidine -- Intermediate -- A, 4-cyano-1-methyl-4-phenyl-
43 piperidine;
44 (212) Pethidine -- Intermediate -- B, ethyl-4-phenylpiperidine-4-
45 carboxylate;
46 (223) Pethidine -- Intermediate -- C, 1-methyl-4-phenylpiperid-
47 ine-4-carboxylic acid;
48 (234) Phenazocine;
49 (245) Piminodine;
50 (256) Racemethorphan;

- 1 (267) Racemorphan;
2 (278) Remifentanil;
3 (289) Sufentanil.

4 (d) Stimulants. Unless specifically excepted or unless listed in an-
5 other schedule, any material, compound, mixture, or preparation which con-
6 tains any quantity of the following substances having a stimulant effect on
7 the central nervous system:

- 8 (1) Amphetamine, its salts, optical isomers, and salts of its optical
9 isomers;
10 (2) Lisdexamfetamine;
11 (3) Methamphetamine, its salts, isomers, and salts of its isomers;
12 (4) Phenmetrazine and its salts;
13 (5) Methylphenidate.

14 (e) Depressants. Unless specifically excepted or unless listed in an-
15 other schedule, any material, compound, mixture, or preparation which con-
16 tains any quantity of the following substances having a depressant effect on
17 the central nervous system, including its salts, isomers, and salts of iso-
18 mers, whenever the existence of such salts, isomers, and salts of isomers is
19 possible within the specific chemical designation:

- 20 (1) Amobarbital;
21 (2) Glutethimide;
22 (3) Pentobarbital;
23 (4) Phencyclidine;
24 (5) Secobarbital.
25 (f) Hallucinogenic substances.

26 (1) Nabilone (another name for nabilone:
27 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hy-
28 droxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one) (21 CFR 1308.12 (f)).

29 (g) Immediate precursors. Unless specifically excepted or unless
30 listed in another schedule, any material, compound, mixture, or preparation
31 which contains any quantity of the following substances:

- 32 (1) Immediate precursor to amphetamine and methamphetamine:
33 (a) Anthranilic acid;
34 (b) Ephedrine;
35 (c) Lead acetate;
36 (d) Methylamine;
37 (e) Methyl formamide;
38 (f) N-methylephedrine;
39 (g) Phenylacetic acid;
40 (h) Phenylacetone;
41 (i) Phenylpropanolamine;
42 (j) Pseudoephedrine.

43 Except that any combination or compound containing ephedrine, or any of
44 its salts and isomers, or phenylpropanolamine or its salts and isomers,
45 or pseudoephedrine, or any of its salts and isomers which is prepared
46 for dispensing or over-the-counter distribution is not a controlled
47 substance for the purpose of this section, unless such substance is pos-
48 sessed, delivered, or possessed with intent to deliver to another with
49 the intent to manufacture methamphetamine, amphetamine or any other
50 controlled substance in violation of section 37-2732, Idaho Code. For



1 purposes of this provision, the requirements of the uniform controlled
2 substances act shall not apply to a manufacturer, wholesaler or re-
3 tailer of over-the-counter products containing the listed substances
4 unless such person possesses, delivers, or possesses with intent to
5 deliver to another the over-the-counter product with intent to manufac-
6 ture a controlled substance.

7 (2) Immediate precursors to phencyclidine (PCP):

8 (a) 1-phenylcyclohexylamine;

9 (b) 1-piperidinocyclohexanecarbonitrile (PCC).

10 (3) Immediate precursor to fentanyl: 4-anilino-N-phenethyl-4-piperi-
11 dine (ANPP).

12 SECTION 3. That Section 37-2711, Idaho Code, be, and the same is hereby
13 amended to read as follows:

14 37-2711. SCHEDULE IV. (a) Schedule IV shall consist of the drugs and
15 other substances, by whatever official name, common or usual name, chemical
16 name, or brand name designated, listed in this section.

17 (b) Narcotic drugs. Unless specifically excepted or unless listed in
18 another schedule, any material, compound, mixture, or preparation contain-
19 ing any of the following narcotic drugs, or their salts calculated as the
20 free anhydrous base or alkaloid, in limited quantities as set forth below:

21 (1) No more than 1 milligram of difenoxin and not less than 25 micro-
22 grams of atropine sulfate per dosage unit;

23 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-
24 3-methyl-2-propionoxybutane)-i;

25 (3) 2- [(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol (in-
26 cluding tramadol), including its salts, optical and geometric isomers,
27 and salts of isomers.

28 (c) Depressants. Unless specifically excepted or unless listed in an-
29 other schedule, any material, compound, mixture, or preparation which con-
30 tains any quantity of the following substances, including its salts, iso-
31 mers, and salts of isomers whenever the existence of such salts, isomers, and
32 salts of isomers is possible within the specific chemical designation:

33 (1) Alfaxalone 5[alpha]-pregnan-3[alpha]-ol-11,20-dione;

34 (2) Alprazolam;

35 (3) Barbital;

36 (4) Bromazepam;

37 (5) Camazepam;

38 (6) Carisoprodol;

39 (7) Chloral betaine;

40 (8) Chloral hydrate;

41 (9) Chlordiazepoxide;

42 (10) Clobazam;

43 (11) Clonazepam;

44 (12) Clorazepate;

45 (13) Clotiazepam;

46 (14) Cloxazolam;

47 (15) Delorazepam;

48 (16) Diazepam;

49 (17) Dichloralphenazone;



- 1 (18) Estazolam;
- 2 (19) Ethchlorvynol;
- 3 (20) Ethinamate;
- 4 (21) Ethyl loflazepate;
- 5 (22) Fludiazepam;
- 6 (23) Flurazepam;
- 7 (24) Fospropofol;
- 8 (25) Halazepam;
- 9 (26) Haloxazolam;
- 10 (27) Ketazolam;
- 11 (28) Lemborexant;
- 12 (29) Loprazolam;
- 13 (2930) Lorazepam;
- 14 (301) Lormetazepam;
- 15 (312) Mebutamate;
- 16 (323) Medazepam;
- 17 (334) Meprobamate;
- 18 (345) Methohexital;
- 19 (356) Methylphenobarbital (mephobarbital);
- 20 (367) Midazolam;
- 21 (378) Nimetazepam;
- 22 (389) Nitrazepam;
- 23 (3940) Nordiazepam;
- 24 (401) Oxazepam;
- 25 (412) Oxazolam;
- 26 (423) Paraldehyde;
- 27 (434) Petrichloral;
- 28 (445) Phenobarbital;
- 29 (456) Pinazepam;
- 30 (467) Prazepam;
- 31 (478) Quazepam;
- 32 (49) Remimazolam;
- 33 (50) Serdexmethylpheniate;
- 34 (4851) Suvorexant;
- 35 (4952) Temazepam;
- 36 (503) Tetrazepam;
- 37 (514) Triazolam;
- 38 (525) Zaleplon;
- 39 (536) Zolpidem;
- 40 (547) Zopiclone.

41 (d) Fenfluramine -- Any material, compound, mixture, or preparation
42 which contains any quantity of the following substances, including its
43 salts, isomers (whether optical, position, or geometric), and salts of such
44 isomers, whenever the existence of such salts, isomers, and salts of isomers
45 is possible:

- 46 (1) Dexfenfluramine;
- 47 (2) Fenfluramine.

48 (e) Stimulants. Unless specifically excepted or unless listed in an-
49 other schedule, any material, compound, mixture, or preparation which con-
50 tains any quantity of the following substances having a stimulant effect on

1 the central nervous system, including its salts, isomers (whether optical,
2 position, or geometric), and salts of such isomers whenever the existence
3 of such salts, isomers, and salts of isomers is possible within the specific
4 chemical designation:

- 5 (1) Cathine ((+)-norpseudoephedrine);
- 6 (2) Diethylpropion;
- 7 (3) Fencamfamin;
- 8 (4) Fenproporex;
- 9 (5) Lorcaserin;
- 10 (6) Mazindol;
- 11 (7) Mefenorex;
- 12 (8) Modafinil;
- 13 (9) Pemoline (including organometallic complexes and chelates
14 thereof);
- 15 (10) Phentermine;
- 16 (11) Pipradrol;
- 17 (12) Sibutramine;
- 18 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 19 (14) Solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol,
20 beta-amino-, carbamate (ester)).

21 (f) Other substances. Unless specifically excepted, or unless listed
22 in another schedule, any material, compound, mixture or preparation which
23 contains any quantity of the following substances, including its salts:

- 24 (1) Pentazocine Brexanolone (3A-hydroxy-5A-pregnan-20-one), allo-
25 pregnanolone;
- 26 (2) Butorphanol (including its optical isomers);
- 27 (3) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2,6-
28 dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-
29 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical
30 isomers) and its salts, isomers, and salts of isomers;
- 31 (4) Pentazocine.

32 (g) The board may except, by rule, any compound, mixture, or prepara-
33 tion containing any depressant substance listed in subsection (c) of this
34 section from the application of all or any part of this act if the compound,
35 mixture, or preparation contains one (1) or more active medicinal ingredi-
36 ents not having a depressant effect on the central nervous system, and if the
37 admixtures are included therein in combinations, quantity, proportion, or
38 concentration that vitiate the potential for abuse of the substances which
39 have a depressant effect on the central nervous system.

40 SECTION 4. That Section 37-2713, Idaho Code, be, and the same is hereby
41 amended to read as follows:

42 37-2713. SCHEDULE V. (a) Schedule V shall consist of the drugs and
43 other substances, by whatever official name, common or usual name, chemical
44 name, or brand name designated, listed in this section.

45 (b) Narcotic drugs. Unless specifically excepted or unless listed in
46 another schedule, any material, compound, mixture, or preparation contain-
47 ing any of the following narcotic drugs and their salts, as set forth below.

48 (c) Narcotic drugs containing nonnarcotic active medicinal ingredi-
49 ents. Any compound, mixture, or preparation containing any of the follow-

1 ing limited quantities of narcotic drugs or salts thereof, which shall in-
2 clude one (1) or more nonnarcotic active medicinal ingredients in sufficient
3 proportion to confer upon the compound, mixture, or preparation, valuable
4 medicinal qualities other than those possessed by the narcotic drug alone:
5 (1) Not more than 200 milligrams of codeine per 100 milliliters or per
6 100 grams;
7 (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters
8 or per 100 grams;
9 (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters
10 or per 100 grams;
11 (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25
12 micrograms of atropine sulfate per dosage unit;
13 (5) Not more than 100 milligrams of opium per 100 milliliters or per 100
14 grams;
15 (6) Not more than 0.5 milligrams difenoxin and not less than 25 micro-
16 grams of atropine sulfate per dosage unit.
17 (d) Other substances. Unless specifically excepted or unless listed
18 in another schedule, any material, compound, mixture or preparation which
19 contains any quantity of the following substances, including its salts:
20 (1) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]bu-
21 tanamide) (also referred to as BRV; UCB-34714; Briviact) (including its
22 salts);
23 (2) Cenobamate[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl]car-
24 bamate;
25 (3) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic
26 acid ethyl ester]-2779;
27 (~~3~~4) Lacosamide;
28 (~~4~~5) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-car-
29 bonyl)pyridine-2-yl)benzamide];
30 (~~5~~6) Pregabalin;
31 (~~6~~7) Pyrovalerone.